Trials / Completed
CompletedNCT04782388
Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants
A Placebo-Controlled, Double-blind, Randomized Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of Staccato alprazolam in healthy Japanese, Chinese, and Caucasian participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alprazolam | Study participants will receive Staccato alprazolam at prespecified time-point. |
| OTHER | Placebo | Study participants will receive Staccato placebo at prespecified time-point. |
Timeline
- Start date
- 2021-03-04
- Primary completion
- 2021-04-26
- Completion
- 2021-04-26
- First posted
- 2021-03-04
- Last updated
- 2021-05-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04782388. Inclusion in this directory is not an endorsement.